The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...

Since the industrial revolution, there has been a collective Western consensus that technology would continue to propel our world forward, further strengthening our personal and professional lives.

Bristol Myers Squibb Co. (BMS) and Eisai Co. Ltd. inked a potential $3.1 billion agreement to co-develop and co-commercialize the antibody-drug conjugate (ADC) MORAb-202 for advanced solid tumors.

Analog devices, Inc. ADI is making strong efforts to bolster presence in the automotive market on the back of robust Battery Management System (BMS) platform. The company’s latest introduction of ASIL ...

Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations two years ago, BMS now has more than 1,240 employees in the ...

Building on a deal first struck in 2019, artificial intelligence (AI) specialist Exscientia Ltd. has agreed to take responsibility for a multitarget drug discovery collaboration with Bristol Myers ...